Skip to content

Author

Y. Najima

We have 6 of 275 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia.

Clonal hematopoiesis (CH) in long-term survivors of allogeneic hematopoietic cell transplant (HCT) remains largely understudied. Using targeted sequencing, we analyzed peripheral blood samples from 101 patients who survived without relapse for more than 10 years after HCT. The median interval from HCT to sample collect...

T. Toya, D. Sadato, C. Hirama et al. · 0 citations
Review 2026

[Integration of novel anti-tumor agents and allogeneic hematopoietic stem cell transplantation].

The use of venetoclax-based regimens, FLT3 inhibitors, and IDH inhibitors has improved treatment outcomes by enabling the achievement of measurable residual disease (MRD)-negative remission, highlighting the importance of maintenance strategies using azacitidine and FLT3 inhibitors, as well as MRD-guided preemptive int...

Y. Najima · 0 citations
Review 2026

[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

A review of the current concepts of post-transplant maintenance therapy in AML/MDS discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.

Y. Najima · 0 citations
Case report Open access Aug 2026

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21)

This case suggests that sequential low-dose GO followed by stepwise DLI may support durable remission when used as a post-transplant maintenance strategy in chemo-refractory AML with adverse cytogenetics, such as t(1;3)(p36.3;q21).

Fumihiko Ouchi, Y. Najima, K. Haraguchi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.